March 2015

Cyramza by Eli Lilly and Company

March 23, 2015

Formulary Drug Review

Cyramza, manufactured by Eli Lilly and Company, is an angiogenesis inhibitor indicated for the treatment of patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with disease progression on or after treatment with prior fluoropyrimidine- or platinum-containing chemotherapy.